as of 01-16-2026 3:53pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 3.1B | IPO Year: | 2018 |
| Target Price: | $38.60 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.26 - $41.57 | Next Earning Date: | 11-03-2025 |
| Revenue: | $69,216,000 | Revenue Growth: | 343.41% |
| Revenue Growth (this year): | 1005.03% | Revenue Growth (next year): | 204.13% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Commercial Officer
Avg Cost/Share
$37.43
Shares
20,533
Total Value
$768,550.19
Owned After
154,514
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$37.43
Shares
66,610
Total Value
$2,493,212.30
Owned After
1,037,528
SEC Form 4
CFO and COO
Avg Cost/Share
$37.43
Shares
36,932
Total Value
$1,382,364.76
Owned After
350,919
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$37.43
Shares
21,142
Total Value
$791,345.06
Owned After
176,883
SEC Form 4
Chief Business Officer
Avg Cost/Share
$37.43
Shares
13,548
Total Value
$507,101.64
Owned After
184,174
SEC Form 4
General Counsel
Avg Cost/Share
$37.43
Shares
27,289
Total Value
$1,021,427.27
Owned After
579,394
SEC Form 4
Chief Human Resource Officer
Avg Cost/Share
$37.43
Shares
13,165
Total Value
$492,765.95
Owned After
140,769
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$37.43
Shares
11,047
Total Value
$413,489.21
Owned After
156,700
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$32.19
Shares
831
Total Value
$26,749.89
Owned After
154,514
SEC Form 4
CFO and COO
Avg Cost/Share
$32.19
Shares
1,166
Total Value
$37,533.54
Owned After
350,919
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Moomaw Scott | LQDA | Chief Commercial Officer | Jan 12, 2026 | Sell | $37.43 | 20,533 | $768,550.19 | 154,514 | |
| JEFFS ROGER | LQDA | Chief Executive Officer | Jan 12, 2026 | Sell | $37.43 | 66,610 | $2,493,212.30 | 1,037,528 | |
| Kaseta Michael | LQDA | CFO and COO | Jan 12, 2026 | Sell | $37.43 | 36,932 | $1,382,364.76 | 350,919 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Jan 12, 2026 | Sell | $37.43 | 21,142 | $791,345.06 | 176,883 | |
| Adair Jason | LQDA | Chief Business Officer | Jan 12, 2026 | Sell | $37.43 | 13,548 | $507,101.64 | 184,174 | |
| Schundler Russell | LQDA | General Counsel | Jan 12, 2026 | Sell | $37.43 | 27,289 | $1,021,427.27 | 579,394 | |
| Krepp Sarah | LQDA | Chief Human Resource Officer | Jan 12, 2026 | Sell | $37.43 | 13,165 | $492,765.95 | 140,769 | |
| Boyle Dana | LQDA | Chief Accounting Officer | Jan 12, 2026 | Sell | $37.43 | 11,047 | $413,489.21 | 156,700 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Dec 1, 2025 | Sell | $32.19 | 831 | $26,749.89 | 154,514 | |
| Kaseta Michael | LQDA | CFO and COO | Dec 1, 2025 | Sell | $32.19 | 1,166 | $37,533.54 | 350,919 |
See how LQDA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.